The company has not received the office action but anticipates that it will file a response to this final office action upon review of the document. The company will appeal the decision to the board of appeals within the Patent Office, if the rejection is maintained.
The Cabilly patent relates to certain methods used to make antibodies and antibody fragments by recombinant DNA technology, as well as recombinant cells and DNA that are used in those methods. Genentech utilizes this technology for many of its own products and has confidential licensing agreements with a number of companies on the Cabilly patent.